Bluejay Diagnostics (BJDX) Asset Writedowns and Impairment (2022 - 2026)

Bluejay Diagnostics has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $2880.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $2880.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $47808.0 (changed N/A YoY), and the FY2025 annual result was $42937.0, up 1158.78% from the prior year.
• Asset Writedowns and Impairment came in at $2880.0 for Q1 2026 at Bluejay Diagnostics, down from $16231.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $27192.0 in Q4 2022 to a low of $2486.0 in Q4 2024.
• The 4-year median for Asset Writedowns and Impairment is $16231.0 (2025), against an average of $15000.0.
• Peak annual rise in Asset Writedowns and Impairment reached 552.9% in 2025, while the deepest fall reached 552.9% in 2025.
• Bluejay Diagnostics' Asset Writedowns and Impairment stood at $27192.0 in 2022, then slumped by 90.86% to $2486.0 in 2024, then jumped by 552.9% to $16231.0 in 2025, then slumped by 82.26% to $2880.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $2880.0 (Q1 2026), $16231.0 (Q4 2025), and $26211.0 (Q3 2025), per Business Quant data.